or Try an Advanced Search...

    Insulin Delivery Stocks List

    Symbol Grade Name % Change
    JNJ D Johnson & Johnson 0.17
    TNDM F Tandem Diabetes Care, Inc. 1.72
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major Medical Devices
    Related Stock Lists: Glucose Insulin Antipsychotic Blood Glucose Monitoring Cardiovascular Disease Caregiver Contact Lens Contact Lenses Diabetes Diabetes Care Diabetes Management Diabetes Mellitus Diabetes Mellitus Type 1 Diagnostic Products Dow Jones Component Endocrine System Endocrinology Energy Products Gastrointestinal General Surgery

    Related ETFs - A few ETFs which own one or more of the above listed Insulin Delivery stocks.

    Symbol Grade Name Weight
    IHE D iShares U.S. Pharmaceutical ETF 22.46
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 7.45
    FLV C American Century Focused Large Cap Value ETF 7.21
    XLV D SPDR Select Sector Fund - Health Care 7.11
    IYH D iShares U.S. Healthcare ETF 6.93
    View all Insulin Delivery ETFs...
    Compare ETFs
    Compare IHE to FLV Compare IHE to FTXH Compare IHE to IYH

        Insulin Delivery Stocks Recent News

        Date Stock Title
        Nov 1 JNJ Stocks that hedge funds moved from long to short in August - Jefferies
        Nov 1 TNDM Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
        Nov 1 JNJ Johnson & Johnson MedTech concludes enrolment for OMNY-AF trial pilot phase
        Nov 1 JNJ J&J Medtech CIO Larry Jones resigns
        Oct 31 JNJ The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
        Oct 31 JNJ Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
        Oct 30 JNJ Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
        Oct 30 TNDM Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
        Oct 29 JNJ J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
        Oct 29 JNJ J&J to seek FDA approval after small-bore Impella heart pump hits trial goal
        Oct 28 JNJ Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
        Oct 28 JNJ DOJ throws wrench into J&J bankruptcy plan to settle talc suits
        Oct 28 JNJ J&J’s $8.2 Billion Talc Settlement Faces January Court Test
        Oct 28 JNJ AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
        Oct 28 JNJ J&J Impella ECP heart pump meets primary endpoint
        Oct 28 JNJ Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
        Oct 28 JNJ JNJ's subcutaneous Tremfya demonstrates efficacy in Crohn's
        Oct 28 JNJ This Johnson & Johnson Insider Reduced Their Stake By 37%
        Oct 28 JNJ TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
        Related Industries: Drug Manufacturers - Major Medical Devices
        Related Stock Lists: Glucose Insulin Antipsychotic Blood Glucose Monitoring Cardiovascular Disease Caregiver Contact Lens Contact Lenses Diabetes Diabetes Care Diabetes Management Diabetes Mellitus Diabetes Mellitus Type 1 Diagnostic Products Dow Jones Component Endocrine System Endocrinology Energy Products Gastrointestinal General Surgery
        Insulin Delivery

        Insulin delivery is the process of administering insulin to a person with diabetes. Insulin is a hormone that helps the body regulate blood sugar levels. Insulin delivery can be done through injections, insulin pumps, or inhaled insulin.

        Browse All Tags